Skip to main content

Enrollment in the Health Benefits for Immigrant Adults (HBIA) program will be temporarily paused effective July 1, 2023.

Enrollment in the Health Benefits for Immigrant Seniors (HBIS) program will be temporarily paused effective Nov. 6, 2023.

Elizabeth M. Whitehorn, Director

Drugs and Therapeutics (D & T) Committee Drugs Under Review for: March 20, 2013

Drug Name Review Type Class Manufacturer
Quillivant XR New Drug Initial Review Stimulants/ADHD Pfizer
Xeljanz New Drug Initial Review Rheumatoid Arthritis Pfizer
Aubagio New Drug Initial Review Multiple Sclerosis Genzyme
Eliquis New Drug Initial Review Oral Anticoagulant Bristol Myers-Squibb
Sklice New Drug Initial Review Pediculicide Sanofi Pasteur
Gattex New Drug Initial Review GLP-2 NPS Pharmaceuticals
Oxtellar XR New Drug Initial Review Anticonvulsant Supernus Pharmaceuticals
Tudorza Pressair New Drug Initial Review Long-acting Anticholingeric Forest
Natroba New Drug Appeal Pediculicide ParaPRO
Brilinta PDL Appeal Platelet Aggregation Inhibitor AstraZeneca
Latuda PDL Appeal Atypical Antipsychotic Sunovion